Information, deadlines and resource documents for U.S. tariff actions and the responses by the rest of the world.
Internationally recognized trade compliance training.
Subscribe to daily updates
The International Trade Commission has instituted investigation 337-TA-1066 to determine whether imports of recombinant factor IX products, which are used for the treatment of hemophilia B, are violating Section 337 of the 1930 Tariff Act by reason of patent infringement.
Complainants Bioverativ Inc., Bioverativ Therapeutics Inc., and Bioverativ U.S. LLC request that after this investigation the ITC issue a limited exclusion order, which would direct U.S. Customs and Border Protection to prohibit the entry of infringing products into the U.S., and cease and desist orders, which would require the named respondents to cease actions that violate Section 337, including selling infringing imported articles out of U.S. inventory. The respondents in this investigation are located in Germany, Switzerland, and the U.S.
September 17, 2020 // Trade Report
September 16, 2020 // Trade Report
September 9, 2020 // Trade Report